ASH 2021 Annual Meeting

Jul 4, 2022

The 63rd ASH Annual Meeting and Exposition organised by the American Society of Hematology will be presented at the Georgia World Congress Center in Atlanta, Georgia – and virtually – from December 11-14, 2021.

This year we will be attending this important meeting for the CML patient advocacy community to discover the newest advances in hematology, review many scientific abstracts highlighting updates on chronic myeloid leukemia and prepare a comprehensive report of of the most critical presentations on CML.

Read more about the agenda to be followed by the CML patient advocates. Please, note all times listed are in US Eastern Time (EST):

– Friday 10th December –

3:00 p.m. – 6:00 p.m. EST
Satellite Symposia Sponsored by Novartis. Aligning the evidence with the patient to individualize treatment considerations along the CML care continuum.
Chair: Jorge E. Cortes, MD.
Speakers: Vivian G. Oehler; MD, Delphine Rea, MD,PhD; Andreas Hochhaus, MD.

– Saturday 11th December –

9:30 AM-11:00 AM
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational I. Oral and Poster Abstracts
55. DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Myeloproliferative Neoplasm Disease Progression Tim Kong, MSc

  • 56. Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms Paola Guglielmelli, MD, PhD
  • 57. Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients Shira Rosenberg, MSc
  • 58. Whole-Genome CRISPR Screening Identifies N-Glycosylation As an Essential Pathway and a Potential Novel Therapeutic Target in CALR-Mutant MPN Anna E. Marneth, PhD
  • 59. MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis Helong Zhao, PhD
  • 60. IL13 Contributes to Fibrotic Progression of the Myeloproliferative Neoplasms Johanna Melo-Cardenas, PhD

9.30 AM-10:15 AM EST
The COVID Crash: Lessons Learned from a World on Pause – Live Q&A.
Panelists: Shruti Chaturvedi, MBBS; Scott Kaatz, DO, MSc; Lise J Estcourt, DPhil, MBBChir, MSc.

This education session will explore the pathophysiology of COVID-19 associated coagulopathy and thrombosis and evidence supporting best practices in management including anticoagulation strategies depending on disease severity and clinical setting. The session will also discuss the role of passive immune therapies including convalescent plasma and monoclonal antibodies in COVID-19.

11:15 AM-12:15 PM
How to Get Published in a Peer-Reviewed Journal
Special-Interest Sessions
Panelists: Nancy Berliner, MD and Andrew W Roberts, PhD, MBBS.

11:30 AM-12:30 PM
Industry Theater: Pfizer’s Leadership Through Science: Driving Innovation in Hematology
Sponsor: Pfizer Inc.
Andy Schmeltz, Dany Habr, MD and Vassiliki Papadimitrakopoulou, MD.

2:00 PM-2:45 PM
CML: Success Breeds More Success – Live Q&A. Education Program
The development of BCR-ABL tyrosine kinase inhibitors revolutionized therapy for chronic myeloid leukemia, causing those who treat CML to shift much of their focus to management of long-term toxicities and the possibility of TKI cessation. In spite of this success, there remain a minority of patients who still progress to advanced phases of CML.

  • Dr. Andreas Hochhaus will discuss TKI discontinuation and strategies to increase the number of eligible patients.
  • Dr. Michael Mauro will discuss life-long TKI therapy, including management of cardiovascular risk factors and other toxicities.
  • Dr. Gabriela Hobbs will discuss advanced phase CML and the management of accelerated and blast phase disease.

2:00 PM-3:30 PM
Identifying and Eliminating Inequity in the Provision of Healthcare
Special Symposium on Quality

This year’s Special Symposium on Quality will focus on examining how systemic inequities impact healthcare quality, and what hematologists can do to promote more equitable provision of healthcare.

  • Equity in Patient Care and Outcomes, Maureen Okam Okam Achebe, MD, MPH.
  • Mechanisms for Change in Health Equity, Lanetta Bronte-Hall, MD, MPH, MSPH.
  • The Social and Moral Determinants of Health / Equity in Healthcare, Kara Odom Walker, MD, MPH.

2:00 PM-2:45 PM
How Can We Ensure That Everyone Who Needs A Transplant Can Get One? – Live Q&A
Panelists: Andrew S. Artz, MD, MS, University of Chicago , Vanderson Rocha, MD, PhD, Hospital Sirio-Libanes, Sao Paulo, Brazil and Navneet S. Majhail, MD, Mayo Clinic, Sarah Cannon.

3:15 PM
Oral and Poster Abstracts Outcomes Research—Myeloid Malignancies: Real World Outcomes
282. Contemporary “Real World” Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States. Rory M. Shallis, MD.

4:00 PM-5:30 PM
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies. Oral and Poster Abstracts.

  • 307. Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic TrialClinically Relevant Abstract. Michael W. Deininger, MD, PhD
  • 308. Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-TherapyClinically Relevant Abstract. Xiaoshuai Zhang1
  • 309. An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. Jorge E. Cortes, MD
  • 310. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 WeeksClinically Relevant Abstract. Michael J. Mauro, MD
  • 311. Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)Clinically Relevant Abstract. Jiang Qian, MD
  • 312. Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial. Mhairi Copland, PhD, MBBChir, FRCP, FRCPath

– Sunday 12th December –

9:30 AM-10:15 AM
AI, Data Science, Computer Vision and the Hematology Laboratory of the Future – Live Q&A
This scientific session includes speakers who are at the forefront of developing and applying computational approaches for the quantitative analysis of tissue and liquid biopsy samples.

11:15 AM-12:15 PM
How to Peer Review a Scientific Paper
Special-Interest Sessions

4:30 PM-6:00 PM
The Role of Real World Data Collection in Hematologic Malignancies

The Role of Real-World Data in Hematologic Malignancy Research (ASH Research Collaborative) Martin S. Tallman, MD; Role of Real-World Data in Hematologic Malignancy Research (HARMONY) John Gribben, MD, DSc, FRCP, FRCPath, FmedSci; Real-World Data Expectations, Challenges, and Potential Solutions to Accelerate Research (ASH Research Collaborative) William A. Wood, MD, MPH; Real-World Data Expectations, Challenges, and Potential Solutions to Accelerate Research (HARMONY) Guillermo Sanz, MD, PhD; Regulatory Perspective on Data sharing and Real-World Data to Generate Real-World Evidence Nicole J. Gormley, MD; Patient’s Viewpoint on Real World Data Sharing Jan Geissler; Multiple Myeloma Real World Data for Research (ASH Research Collaborative) Kenneth C. Anderson, MD; Multiple Myeloma Real-World Data for Research (HARMONY) Mario Boccadoro; Acute Myeloid Leukemia Real World Data for Research (ASH Research Collaborative) Laura C. Michaelis, MD; Acute Myeloid Leukemia Real World Data for Research (HARMONY) Lars Bullinger.


Conclusion Jesus Maria Hernández-Rivas, MD PhD.

4:30 PM-5:15 PM
Financial Stewardship In an Era of Hematologic Advances in Care: Whose Value? What Price? – Live Q&A
Spotlight Sessions

– Monday 13th December – 

10:30 AM-12:00 PM
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Progress with response prediction and TKI discontinuation. Oral and Poster Abstracts
Moderators: Jorge E. Cortes, MD, and Mhairi Copland, PhD, MBBChir, FRCP, FRCPath.

  • 631. Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Koji Sasaki, MD, PhD
  • 632. A Predictive Score for Failure-Free Survival in Persons with Chronic Myeloid Leukemia Receiving Imatinib. Xiaoshuai Zhang
  • 633. FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI StudyClinically Relevant Abstract. Francois-Xavier Mahon, MD, PhD
  • 634. COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. Katia B Pagnano, MD, PhD
  • 635. Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. Delphine Rea, MD, PhD
  • 636. A Predictive Score for Outcomes of Tyrosine Kinase-Inhibitor Therapy in Persons with Chronic Myeloid Leukaemia Presenting in Accelerated Phase. Sen Yang, MD.

10:30 AM-12:00 PM
ASH-FDA Joint Symposium on Newly Approved Drugs: Treatment Landscape in the Era of Novel Therapies
Special-Interest Sessions

  • Treatment Landscape of Chronic Myeloid Leukemia: Asciminib. Gulsum E Pamuk, MD
  • Treatment Landscape of Chronic Myeloid Leukemia – Clinical Discussant. Ravi Bhatia, MD

10:30 AM-11:15 AM
Approved, But Should We Use It? – Are the New Trial Designs Effective? – Live Q&A
Spotlight Sessions
Chair: Jonathan W. Friedberg, MD
Panelists: Sumithra J Mandrekar, PhD; Laurie H. Sehn, MD; Ann T. Farrell, MD, and Stephanie Seremetis, MD.

12:15 PM-1:15 PM
ASH Advances COVID Research 2021
This session is designed to highlight the most significant submitted abstracts focused on COVID-19 in three general areas of focus: COVID-19 outcomes in hematology patients, COVID-19-related thrombosis, and COVID-19 immunology and vaccine responses.

4:30 PM-4:45 PM
906. Outcomes Research—Myeloid Malignancies: Health Equity and Disparities. Oral and Poster Abstracts
841. Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies. Karen Sweiss, PharmD.

– Tuesday 14th December –

12:30 PM-2:00 PM
Best of ASH

Follow the conversation on our social media channels with #CML #ASH21 #PatientAdvocacy

The latest news from the network

APPIS is back! Register now for APPIS 2024!

APPIS is back! Register now for APPIS 2024!

The Alliance and Partnerships for Patient Innovation and Solutions (APPIS) is an organization that aims to bring together individuals and groups to create innovative solutions for patients. With its...

read more